- Tempest Therapeutics Inc To Discuss Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma Call TranscriptOct 11, 2023
- Tempest Therapeutics Inc at HC Wainwright Investment Conference - New York TranscriptSep 11, 2023
- Tempest Therapeutics Inc Annual Shareholders Meeting TranscriptJun 15, 2023
- Tempest Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Tempest Therapeutics Inc To Discuss Phase 1b/2 Combination Study of TPST-1120 in First-Line HCC Data Call TranscriptApr 28, 2023
- Tempest Therapeutics Inc at Piper Sandler Healthcare Conference TranscriptNov 29, 2022
- Tempest Therapeutics Inc Annual Shareholders Meeting TranscriptJun 17, 2022
- Tempest Therapeutics Inc At ASCO Call TranscriptJun 05, 2022
- Millendo Therapeutics Inc And Tempest Therapeutics Inc Merger - M&A Call TranscriptMar 29, 2021
Tempest Therapeutics Inc at Jefferies Healthcare Conference Transcript
Tempest is a public company. I will be making forward-looking statements today. Please see our SEC filings.
Tempress represents a diversified oncology investment opportunity. We have four programs spanning two drugs in clinic right now. A preclinical program that is late in the preclinical setting that we are optimistic will be in clinic next year and an undisclosed opportunity that is we think not being explored by anyone else in the industry at this point.
The four programs that we have are mechanistically independent and we think represent four unique shots on goal. Each of them standing on their own in terms of an opportunity in significant cancer indications. We are funded through 2024, and through potential value inflection point.
The oncology pipeline is shown here. The first compound TPST-1120 is a novel oral inhibitor of the transcription of the ligand activated transcription factor of PPAR alpha. This drug will be a first-in-class compound if approved. The TPST-1120 has completed a first -- our Phase-1 program
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)